Does the media prefer PRQR or CABA?

In the previous week, Cabaletta Bio had 6 more articles in the media than ProQR Therapeutics. MarketBeat recorded 7 mentions for Cabaletta Bio and 1 mentions for ProQR Therapeutics. ProQR Therapeutics' average media sentiment score of 1.19 beat Cabaletta Bio's score of 0.23 indicating that ProQR Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ProQR Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Cabaletta Bio 1 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to PRQR or DNA?

In the previous week, ProQR Therapeutics and ProQR Therapeutics both had 1 articles in the media. Ginkgo Bioworks' average media sentiment score of 1.65 beat ProQR Therapeutics' score of 1.19 indicating that Ginkgo Bioworks is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ProQR Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Ginkgo Bioworks 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Does the media refer more to PRQR or CTMX?

In the previous week, CytomX Therapeutics had 2 more articles in the media than ProQR Therapeutics. MarketBeat recorded 3 mentions for CytomX Therapeutics and 1 mentions for ProQR Therapeutics. ProQR Therapeutics' average media sentiment score of 1.19 beat CytomX Therapeutics' score of 0.59 indicating that ProQR Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ProQR Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive CytomX Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to PRQR or ALT?

In the previous week, ProQR Therapeutics and ProQR Therapeutics both had 1 articles in the media. ProQR Therapeutics' average media sentiment score of 1.19 beat Altimmune's score of 0.49 indicating that ProQR Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ProQR Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Altimmune 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is PRQR or VALN more profitable?

Valneva has a net margin of -88.87% compared to ProQR Therapeutics' net margin of -331.33%. ProQR Therapeutics' return on equity of -84.87% beat Valneva's return on equity. Company Net Margins Return on Equity Return on Assets ProQR Therapeutics -331.33% -84.87% -37.78% Valneva -88.87% -107.63% -33.02%

Does the media favor PRQR or VALN?

In the previous week, Valneva had 1 more articles in the media than ProQR Therapeutics. MarketBeat recorded 2 mentions for Valneva and 1 mentions for ProQR Therapeutics. ProQR Therapeutics' average media sentiment score of 1.19 beat Valneva's score of 0.20 indicating that ProQR Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ProQR Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Valneva 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

ProQR Therapeutics (PRQR) Competitors

$1.53 +0.03 (+2.00%)

Closing price 04:00 PM Eastern

Extended Trading

$1.54 +0.01 (+0.39%)

As of 07:53 PM Eastern

Compare

PRQR vs. CABA, DNA, CTMX, ALT, and VALN

Should you buy ProQR Therapeutics stock or one of its competitors? MarketBeat compares ProQR Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with ProQR Therapeutics include Cabaletta Bio (CABA), Ginkgo Bioworks (DNA), CytomX Therapeutics (CTMX), Altimmune (ALT), and Valneva (VALN). These companies are all part of the "pharmaceutical products" industry.

How does ProQR Therapeutics compare to Cabaletta Bio?

ProQR Therapeutics (NASDAQ:PRQR) and Cabaletta Bio (NASDAQ:CABA) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, institutional ownership, dividends, analyst recommendations, profitability, valuation, risk and media sentiment.

Cabaletta Bio has a net margin of 0.00% compared to ProQR Therapeutics' net margin of -331.33%. ProQR Therapeutics' return on equity of -84.87% beat Cabaletta Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ProQR Therapeutics	-331.33%	-84.87%	-37.78%
Cabaletta Bio	N/A	-131.58%	-96.46%

ProQR Therapeutics has higher revenue and earnings than Cabaletta Bio. ProQR Therapeutics is trading at a lower price-to-earnings ratio than Cabaletta Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ProQR Therapeutics	$17.99M	8.96	-$47.73M	-$0.50	N/A
Cabaletta Bio	N/A	N/A	-$167.86M	-$1.96	N/A

ProQR Therapeutics has a beta of 0.07, meaning that its share price is 93% less volatile than the broader market. Comparatively, Cabaletta Bio has a beta of 3.21, meaning that its share price is 221% more volatile than the broader market.

32.7% of ProQR Therapeutics shares are owned by institutional investors. 8.4% of ProQR Therapeutics shares are owned by company insiders. Comparatively, 6.4% of Cabaletta Bio shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

In the previous week, Cabaletta Bio had 6 more articles in the media than ProQR Therapeutics. MarketBeat recorded 7 mentions for Cabaletta Bio and 1 mentions for ProQR Therapeutics. ProQR Therapeutics' average media sentiment score of 1.19 beat Cabaletta Bio's score of 0.23 indicating that ProQR Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ProQR Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Cabaletta Bio	1 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

ProQR Therapeutics currently has a consensus target price of $7.25, indicating a potential upside of 373.86%. Cabaletta Bio has a consensus target price of $15.50, indicating a potential upside of 384.38%. Given Cabaletta Bio's higher possible upside, analysts plainly believe Cabaletta Bio is more favorable than ProQR Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ProQR Therapeutics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63
Cabaletta Bio	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57

Summary

ProQR Therapeutics beats Cabaletta Bio on 10 of the 15 factors compared between the two stocks.

How does ProQR Therapeutics compare to Ginkgo Bioworks?

ProQR Therapeutics (NASDAQ:PRQR) and Ginkgo Bioworks (NYSE:DNA) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their valuation, profitability, institutional ownership, media sentiment, earnings, risk, dividends and analyst recommendations.

32.7% of ProQR Therapeutics shares are held by institutional investors. Comparatively, 78.6% of Ginkgo Bioworks shares are held by institutional investors. 8.4% of ProQR Therapeutics shares are held by insiders. Comparatively, 12.7% of Ginkgo Bioworks shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

ProQR Therapeutics currently has a consensus target price of $7.25, suggesting a potential upside of 373.86%. Ginkgo Bioworks has a consensus target price of $8.50, suggesting a potential upside of 5.26%. Given ProQR Therapeutics' stronger consensus rating and higher probable upside, equities analysts clearly believe ProQR Therapeutics is more favorable than Ginkgo Bioworks.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ProQR Therapeutics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63
Ginkgo Bioworks	2 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.67

ProQR Therapeutics has higher earnings, but lower revenue than Ginkgo Bioworks. ProQR Therapeutics is trading at a lower price-to-earnings ratio than Ginkgo Bioworks, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ProQR Therapeutics	$17.99M	8.96	-$47.73M	-$0.50	N/A
Ginkgo Bioworks	$170.15M	3.10	-$312.76M	-$5.36	N/A

Ginkgo Bioworks has a net margin of -215.41% compared to ProQR Therapeutics' net margin of -331.33%. Ginkgo Bioworks' return on equity of -56.08% beat ProQR Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ProQR Therapeutics	-331.33%	-84.87%	-37.78%
Ginkgo Bioworks	-215.41%	-56.08%	-26.06%

In the previous week, ProQR Therapeutics and ProQR Therapeutics both had 1 articles in the media. Ginkgo Bioworks' average media sentiment score of 1.65 beat ProQR Therapeutics' score of 1.19 indicating that Ginkgo Bioworks is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ProQR Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Ginkgo Bioworks	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

ProQR Therapeutics has a beta of 0.07, indicating that its share price is 93% less volatile than the broader market. Comparatively, Ginkgo Bioworks has a beta of 1.79, indicating that its share price is 79% more volatile than the broader market.

Summary

Ginkgo Bioworks beats ProQR Therapeutics on 9 of the 15 factors compared between the two stocks.

How does ProQR Therapeutics compare to CytomX Therapeutics?

ProQR Therapeutics (NASDAQ:PRQR) and CytomX Therapeutics (NASDAQ:CTMX) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, dividends, profitability, risk, valuation, earnings, analyst recommendations and media sentiment.

ProQR Therapeutics has a beta of 0.07, meaning that its share price is 93% less volatile than the broader market. Comparatively, CytomX Therapeutics has a beta of 2.08, meaning that its share price is 108% more volatile than the broader market.

CytomX Therapeutics has a net margin of -166.40% compared to ProQR Therapeutics' net margin of -331.33%. CytomX Therapeutics' return on equity of -36.61% beat ProQR Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ProQR Therapeutics	-331.33%	-84.87%	-37.78%
CytomX Therapeutics	-166.40%	-36.61%	-28.02%

ProQR Therapeutics currently has a consensus price target of $7.25, indicating a potential upside of 373.86%. CytomX Therapeutics has a consensus price target of $12.10, indicating a potential upside of 311.56%. Given ProQR Therapeutics' higher possible upside, equities analysts plainly believe ProQR Therapeutics is more favorable than CytomX Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ProQR Therapeutics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63
CytomX Therapeutics	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.91

CytomX Therapeutics has higher revenue and earnings than ProQR Therapeutics. CytomX Therapeutics is trading at a lower price-to-earnings ratio than ProQR Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ProQR Therapeutics	$17.99M	8.96	-$47.73M	-$0.50	N/A
CytomX Therapeutics	$76.20M	6.57	-$17.37M	-$0.41	N/A

32.7% of ProQR Therapeutics shares are owned by institutional investors. Comparatively, 67.8% of CytomX Therapeutics shares are owned by institutional investors. 8.4% of ProQR Therapeutics shares are owned by insiders. Comparatively, 6.6% of CytomX Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

In the previous week, CytomX Therapeutics had 2 more articles in the media than ProQR Therapeutics. MarketBeat recorded 3 mentions for CytomX Therapeutics and 1 mentions for ProQR Therapeutics. ProQR Therapeutics' average media sentiment score of 1.19 beat CytomX Therapeutics' score of 0.59 indicating that ProQR Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ProQR Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
CytomX Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

CytomX Therapeutics beats ProQR Therapeutics on 12 of the 17 factors compared between the two stocks.

How does ProQR Therapeutics compare to Altimmune?

ProQR Therapeutics (NASDAQ:PRQR) and Altimmune (NASDAQ:ALT) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their analyst recommendations, risk, profitability, valuation, dividends, institutional ownership, earnings and media sentiment.

ProQR Therapeutics has a beta of 0.07, suggesting that its share price is 93% less volatile than the broader market. Comparatively, Altimmune has a beta of 0.21, suggesting that its share price is 79% less volatile than the broader market.

ProQR Therapeutics has a net margin of -331.33% compared to Altimmune's net margin of -214,860.98%. Altimmune's return on equity of -42.57% beat ProQR Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ProQR Therapeutics	-331.33%	-84.87%	-37.78%
Altimmune	-214,860.98%	-42.57%	-35.57%

ProQR Therapeutics has higher revenue and earnings than Altimmune. ProQR Therapeutics is trading at a lower price-to-earnings ratio than Altimmune, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ProQR Therapeutics	$17.99M	8.96	-$47.73M	-$0.50	N/A
Altimmune	$40K	13,272.58	-$88.09M	-$0.93	N/A

ProQR Therapeutics presently has a consensus price target of $7.25, indicating a potential upside of 373.86%. Altimmune has a consensus price target of $16.67, indicating a potential upside of 510.50%. Given Altimmune's higher possible upside, analysts plainly believe Altimmune is more favorable than ProQR Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ProQR Therapeutics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63
Altimmune	2 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.50

32.7% of ProQR Therapeutics shares are owned by institutional investors. Comparatively, 78.1% of Altimmune shares are owned by institutional investors. 8.4% of ProQR Therapeutics shares are owned by company insiders. Comparatively, 1.6% of Altimmune shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

In the previous week, ProQR Therapeutics and ProQR Therapeutics both had 1 articles in the media. ProQR Therapeutics' average media sentiment score of 1.19 beat Altimmune's score of 0.49 indicating that ProQR Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ProQR Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Altimmune	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Altimmune beats ProQR Therapeutics on 8 of the 15 factors compared between the two stocks.

How does ProQR Therapeutics compare to Valneva?

ProQR Therapeutics (NASDAQ:PRQR) and Valneva (NASDAQ:VALN) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, institutional ownership, earnings, media sentiment, analyst recommendations, risk, dividends and valuation.

ProQR Therapeutics has a beta of 0.07, suggesting that its share price is 93% less volatile than the broader market. Comparatively, Valneva has a beta of 1.75, suggesting that its share price is 75% more volatile than the broader market.

In the previous week, Valneva had 1 more articles in the media than ProQR Therapeutics. MarketBeat recorded 2 mentions for Valneva and 1 mentions for ProQR Therapeutics. ProQR Therapeutics' average media sentiment score of 1.19 beat Valneva's score of 0.20 indicating that ProQR Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ProQR Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Valneva	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

ProQR Therapeutics presently has a consensus target price of $7.25, indicating a potential upside of 373.86%. Valneva has a consensus target price of $11.98, indicating a potential upside of 124.25%. Given ProQR Therapeutics' stronger consensus rating and higher probable upside, research analysts plainly believe ProQR Therapeutics is more favorable than Valneva.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ProQR Therapeutics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63
Valneva	2 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.20

ProQR Therapeutics has higher earnings, but lower revenue than Valneva. ProQR Therapeutics is trading at a lower price-to-earnings ratio than Valneva, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ProQR Therapeutics	$17.99M	8.96	-$47.73M	-$0.50	N/A
Valneva	$197.56M	2.56	-$130.33M	-$1.87	N/A

Valneva has a net margin of -88.87% compared to ProQR Therapeutics' net margin of -331.33%. ProQR Therapeutics' return on equity of -84.87% beat Valneva's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ProQR Therapeutics	-331.33%	-84.87%	-37.78%
Valneva	-88.87%	-107.63%	-33.02%

32.7% of ProQR Therapeutics shares are owned by institutional investors. Comparatively, 11.4% of Valneva shares are owned by institutional investors. 8.4% of ProQR Therapeutics shares are owned by insiders. Comparatively, 14.9% of Valneva shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Summary

ProQR Therapeutics beats Valneva on 9 of the 16 factors compared between the two stocks.

Get ProQR Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PRQR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PRQR vs. The Competition

Export

Metric	ProQR Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$158.04M	$3.34B	$6.49B	$11.99B
Dividend Yield	N/A	2.30%	2.67%	5.57%
P/E Ratio	-3.06	18.61	23.92	23.74
Price / Sales	8.96	298.40	507.55	107.95
Price / Cash	N/A	51.45	26.99	37.25
Price / Book	2.89	8.04	10.28	6.78
Net Income	-$47.73M	$23.89M	$3.57B	$337.51M
7 Day Performance	7.75%	-5.97%	-1.43%	-2.72%
1 Month Performance	-3.16%	2.78%	3.27%	1.87%
1 Year Performance	-19.90%	36.26%	23.37%	26.60%

ProQR Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PRQR ProQR Therapeutics	3.0509 of 5 stars	$1.53 +2.0%	$7.25 +373.9%	-21.5%	$158.04M	$17.99M	N/A	180	Positive News Gap Up
CABA Cabaletta Bio	2.9567 of 5 stars	$3.68 +0.3%	$15.50 +321.2%	+31.0%	$598.41M	N/A	N/A	50	News Coverage
DNA Ginkgo Bioworks	1.9653 of 5 stars	$9.31 +1.8%	$8.50 -8.7%	+7.9%	$597.07M	$170.15M	N/A	640	Positive News Gap Up High Trading Volume
CTMX CytomX Therapeutics	2.6344 of 5 stars	$3.16 -8.4%	$12.10 +282.9%	+13.6%	$587.14M	$76.20M	N/A	170
ALT Altimmune	1.9839 of 5 stars	$2.90 -3.7%	$16.67 +474.7%	-51.8%	$585.37M	$40K	N/A	50	News Coverage

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PRQR) was last updated on 6/8/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

ProQR Therapeutics (PRQR) Competitors

PRQR vs. CABA, DNA, CTMX, ALT, and VALN

How does ProQR Therapeutics compare to Cabaletta Bio?

Summary

How does ProQR Therapeutics compare to Ginkgo Bioworks?

Summary

How does ProQR Therapeutics compare to CytomX Therapeutics?

Summary

How does ProQR Therapeutics compare to Altimmune?

Summary

How does ProQR Therapeutics compare to Valneva?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PRQR vs. The Competition

ProQR Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

ProQR Therapeutics (PRQR) Competitors

PRQR vs. CABA, DNA, CTMX, ALT, and VALN

How does ProQR Therapeutics compare to Cabaletta Bio?

Is PRQR or CABA more profitable?

Which has higher valuation and earnings, PRQR or CABA?

Which has more volatility and risk, PRQR or CABA?

Do institutionals & insiders believe in PRQR or CABA?

Does the media prefer PRQR or CABA?

Do analysts prefer PRQR or CABA?

Summary

How does ProQR Therapeutics compare to Ginkgo Bioworks?

Do insiders and institutionals hold more shares of PRQR or DNA?

Do analysts prefer PRQR or DNA?

Which has higher valuation and earnings, PRQR or DNA?

Is PRQR or DNA more profitable?

Does the media refer more to PRQR or DNA?

Which has more risk and volatility, PRQR or DNA?

Summary

How does ProQR Therapeutics compare to CytomX Therapeutics?

Which has more volatility & risk, PRQR or CTMX?

Is PRQR or CTMX more profitable?

Do analysts recommend PRQR or CTMX?

Which has higher valuation and earnings, PRQR or CTMX?

Do institutionals & insiders believe in PRQR or CTMX?

Does the media refer more to PRQR or CTMX?

Summary

How does ProQR Therapeutics compare to Altimmune?

Which has more volatility & risk, PRQR or ALT?

Is PRQR or ALT more profitable?

Which has higher earnings and valuation, PRQR or ALT?

Do analysts rate PRQR or ALT?

Do institutionals and insiders have more ownership in PRQR or ALT?

Does the media refer more to PRQR or ALT?

Summary

How does ProQR Therapeutics compare to Valneva?

Which has more risk and volatility, PRQR or VALN?

Does the media favor PRQR or VALN?

Do analysts prefer PRQR or VALN?

Which has better valuation & earnings, PRQR or VALN?

Is PRQR or VALN more profitable?

Do institutionals and insiders believe in PRQR or VALN?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PRQR vs. The Competition

ProQR Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools